<?xml version="1.0" encoding="utf-8"?>
<File id="73">
  <Title><![CDATA[<p>How much will the vaccine cost?</p>]]></Title>
  <HtmlTextKey><![CDATA[]]></HtmlTextKey>
  <HtmlText><![CDATA[<p>It is too early for GSK to confirm the price of RTS,S during this development phase. In January 2010, GSK committed to setting a price which covers costs of manufacturing the vaccine and a small return of 5% to be reinvested in R&amp;D for next generation malaria vaccines or for other treatments for diseases of the developing world. GSK also committed to evaluate any possibility that would allow limiting the cost of manufacturing<sup>(a)</sup>.</p>]]></HtmlText>
  <Topic>PRICING AND FINANCING</Topic>
  <SubTopic>GENERAL</SubTopic>
  <References><![CDATA[<ol start="1" style="list-style-type:lower-alpha">
	<li><em>Witty A. New Strategies For Innovation In Global Health: A Pharmaceutical Industry Perspective. Health Affairs 2011; 30: 118-26.</em></li>
</ol>]]></References>
  <pdf>xml/content/73/73.pdf</pdf>
  <docx>xml/content/73/73.docx</docx>
  <contentLastUpdated>2015-12-15</contentLastUpdated>
  <RelatedFiles />
</File>